FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592991635> ?p ?o ?g. }

• W2592991635 endingPage "617.e3" @default.
• W2592991635 startingPage "610" @default.
• W2592991635 abstract "Abstract Background The Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy (PREVAIL) trial was unique as it included patients with visceral disease. This analysis was designed to describe outcomes for the subgroup of men from PREVAIL with specific sites of visceral disease to help clinicians understand how these patients responded to enzalutamide prior to chemotherapy. Patients and Methods Prespecified analyses examined the coprimary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) only. All other efficacy analyses were post hoc. The visceral subgroup was divided into liver or lung subsets. Patients with both liver and lung metastases were included in the liver subset. Results Of the 1717 patients in PREVAIL, 204 (12%) had visceral metastases at screening (liver only or liver/lung metastases, n = 74; lung only metastases, n = 130). In patients with liver metastases, enzalutamide was associated with an improvement in rPFS (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.22-0.90) but not OS (HR, 1.04; 95% CI, 0.57-1.87). In patients with lung metastases only, the HR for rPFS (0.14; 95% CI, 0.06-0.36) and the HR for OS (0.59; 95% CI, 0.33-1.06) favored enzalutamide over placebo. Patients with liver metastases had worse outcomes than those with lung metastases, regardless of treatment. Enzalutamide was well tolerated in patients with visceral disease. Conclusions Enzalutamide is an active first-line treatment option for men with asymptomatic or mildly symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer and visceral disease. Patients with lung-only disease fared better than patients with liver disease, regardless of treatment." @default.
• W2592991635 created "2017-03-16" @default.
• W2592991635 creator A5001591556 @default.
• W2592991635 creator A5004985848 @default.
• W2592991635 creator A5016173669 @default.
• W2592991635 creator A5020692060 @default.
• W2592991635 creator A5027991868 @default.
• W2592991635 creator A5031897059 @default.
• W2592991635 creator A5048477205 @default.
• W2592991635 creator A5052694721 @default.
• W2592991635 creator A5059942977 @default.
• W2592991635 creator A5067016693 @default.
• W2592991635 creator A5072378199 @default.
• W2592991635 creator A5085439313 @default.
• W2592991635 creator A5088312939 @default.
• W2592991635 creator A5088951258 @default.
• W2592991635 creator A5091696839 @default.
• W2592991635 date "2017-10-01" @default.
• W2592991635 modified "2023-10-16" @default.
• W2592991635 title "Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial" @default.
• W2592991635 cites W1904433804 @default.
• W2592991635 cites W1963765725 @default.
• W2592991635 cites W1985734141 @default.
• W2592991635 cites W2003021334 @default.
• W2592991635 cites W2080439368 @default.
• W2592991635 cites W2103959341 @default.
• W2592991635 cites W2110534364 @default.
• W2592991635 cites W2120292596 @default.
• W2592991635 cites W2123526148 @default.
• W2592991635 cites W2137467802 @default.
• W2592991635 cites W2148643283 @default.
• W2592991635 cites W2159771669 @default.
• W2592991635 cites W2165542862 @default.
• W2592991635 cites W2166918329 @default.
• W2592991635 cites W2167331614 @default.
• W2592991635 cites W2298315650 @default.
• W2592991635 doi "https://doi.org/10.1016/j.clgc.2017.02.007" @default.
• W2592991635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28344102" @default.
• W2592991635 hasPublicationYear "2017" @default.
• W2592991635 type Work @default.
• W2592991635 sameAs 2592991635 @default.
• W2592991635 citedByCount "21" @default.
• W2592991635 countsByYear W25929916352017 @default.
• W2592991635 countsByYear W25929916352018 @default.
• W2592991635 countsByYear W25929916352019 @default.
• W2592991635 countsByYear W25929916352020 @default.
• W2592991635 countsByYear W25929916352021 @default.
• W2592991635 countsByYear W25929916352022 @default.
• W2592991635 crossrefType "journal-article" @default.
• W2592991635 hasAuthorship W2592991635A5001591556 @default.
• W2592991635 hasAuthorship W2592991635A5004985848 @default.
• W2592991635 hasAuthorship W2592991635A5016173669 @default.
• W2592991635 hasAuthorship W2592991635A5020692060 @default.
• W2592991635 hasAuthorship W2592991635A5027991868 @default.
• W2592991635 hasAuthorship W2592991635A5031897059 @default.
• W2592991635 hasAuthorship W2592991635A5048477205 @default.
• W2592991635 hasAuthorship W2592991635A5052694721 @default.
• W2592991635 hasAuthorship W2592991635A5059942977 @default.
• W2592991635 hasAuthorship W2592991635A5067016693 @default.
• W2592991635 hasAuthorship W2592991635A5072378199 @default.
• W2592991635 hasAuthorship W2592991635A5085439313 @default.
• W2592991635 hasAuthorship W2592991635A5088312939 @default.
• W2592991635 hasAuthorship W2592991635A5088951258 @default.
• W2592991635 hasAuthorship W2592991635A5091696839 @default.
• W2592991635 hasConcept C121608353 @default.
• W2592991635 hasConcept C126322002 @default.
• W2592991635 hasConcept C143998085 @default.
• W2592991635 hasConcept C2776551883 @default.
• W2592991635 hasConcept C2779134260 @default.
• W2592991635 hasConcept C2779256933 @default.
• W2592991635 hasConcept C2780192828 @default.
• W2592991635 hasConcept C61367390 @default.
• W2592991635 hasConcept C71315377 @default.
• W2592991635 hasConcept C71924100 @default.
• W2592991635 hasConceptScore W2592991635C121608353 @default.
• W2592991635 hasConceptScore W2592991635C126322002 @default.
• W2592991635 hasConceptScore W2592991635C143998085 @default.
• W2592991635 hasConceptScore W2592991635C2776551883 @default.
• W2592991635 hasConceptScore W2592991635C2779134260 @default.
• W2592991635 hasConceptScore W2592991635C2779256933 @default.
• W2592991635 hasConceptScore W2592991635C2780192828 @default.
• W2592991635 hasConceptScore W2592991635C61367390 @default.
• W2592991635 hasConceptScore W2592991635C71315377 @default.
• W2592991635 hasConceptScore W2592991635C71924100 @default.
• W2592991635 hasIssue "5" @default.
• W2592991635 hasLocation W25929916351 @default.
• W2592991635 hasOpenAccess W2592991635 @default.
• W2592991635 hasPrimaryLocation W25929916351 @default.
• W2592991635 hasRelatedWork W2309274182 @default.
• W2592991635 hasRelatedWork W2414042649 @default.
• W2592991635 hasRelatedWork W2529483221 @default.
• W2592991635 hasRelatedWork W2590294003 @default.
• W2592991635 hasRelatedWork W3015286180 @default.
• W2592991635 hasRelatedWork W3023947295 @default.
• W2592991635 hasRelatedWork W3132581442 @default.
• W2592991635 hasRelatedWork W3197069188 @default.
• W2592991635 hasRelatedWork W4229076799 @default.
• W2592991635 hasRelatedWork W4285472624 @default.

• next